Literature DB >> 20717673

Effect of 1-(1-Naphtylmethyl)-piperazine, an efflux pump inhibitor, on antimicrobial drug susceptibilities of clinical Acinetobacter baumannii isolates.

Ahmet Yilmaz Coban1, Akif Koray Guney, Yeliz Tanriverdi Cayci, Belma Durupinar.   

Abstract

In this study, the effects of 1-(1-naphtylmethyl)-piperazine (NMP), an efflux pump inhibitor, on antimicrobial drug susceptibilities of 42 clinical Acinetobacter baumannii isolates were investigated by the disc diffusion method. The inhibition zone diameters of antibiotic discs were tested in the presence and absence of NMP and then these zone diameters were compared. Presence of NMP restored ciprofloxacin susceptibility in 15 intermediate and 2 resistant isolates. One ciprofloxacin resistant isolate became intermediate in the presence of NMP. One isolate resistant to gentamicin became intermediate with NMP. Interestingly, one isolate susceptible to meropenem became resistant in the presence of NMP. Although NMP increased the inhibition zone diameters of some of the tested antibiotics against the resistant isolates, the increase was not enough to restore susceptibility. In conclusion, the presence of NMP increases the zone diameters of ciprofloxacin and levofloxacin. Intermediate strains become susceptible but the resistant isolates do not.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20717673     DOI: 10.1007/s00284-010-9736-9

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  10 in total

1.  Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454.

Authors:  S Magnet; P Courvalin; T Lambert
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli.

Authors:  Winfried V Kern; Petra Steinke; Anja Schumacher; Sabine Schuster; Heike von Baum; Jürgen A Bohnert
Journal:  J Antimicrob Chemother       Date:  2005-12-14       Impact factor: 5.790

3.  An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients.

Authors:  L Fierobe; J C Lucet; D Decré; C Muller-Serieys; A Deleuze; M L Joly-Guillou; J Mantz; J M Desmonts
Journal:  Infect Control Hosp Epidemiol       Date:  2001-01       Impact factor: 3.254

4.  Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli.

Authors:  Anja Schumacher; Petra Steinke; Jürgen A Bohnert; Murat Akova; Daniel Jonas; Winfried V Kern
Journal:  J Antimicrob Chemother       Date:  2005-12-14       Impact factor: 5.790

Review 5.  Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii.

Authors:  Jordi Vila; Sara Martí; Javier Sánchez-Céspedes
Journal:  J Antimicrob Chemother       Date:  2007-02-26       Impact factor: 5.790

6.  A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates.

Authors:  Ahmet Yilmaz Coban; Bora Ekinci; Belma Durupinar
Journal:  Chemotherapy       Date:  2004-04       Impact factor: 2.544

7.  Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.

Authors:  Vijaya Bharathi Srinivasan; Govindan Rajamohan; Wondwossen A Gebreyes
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

8.  Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide.

Authors:  Stefanie Pannek; Paul G Higgins; Petra Steinke; Daniel Jonas; Murat Akova; Jürgen A Bohnert; Harald Seifert; Winfried V Kern
Journal:  J Antimicrob Chemother       Date:  2006-03-10       Impact factor: 5.790

9.  Paradoxical effect of 1-(1-naphthylmethyl)-piperazine on resistance to tetracyclines in multidrug-resistant Acinetobacter baumannii.

Authors:  D C Bean; D W Wareham
Journal:  J Antimicrob Chemother       Date:  2008-12-04       Impact factor: 5.790

Review 10.  Acinetobacter outbreaks, 1977-2000.

Authors:  Maria Virginia Villegas; Alan I Hartstein
Journal:  Infect Control Hosp Epidemiol       Date:  2003-04       Impact factor: 3.254

  10 in total
  4 in total

1.  Phenotypic and molecular characterization of Acinetobacter clinical isolates obtained from inmates of California correctional facilities.

Authors:  Galarah D Golanbar; Christopher K Lam; Yi-Ming Chu; Carla Cueva; Stephanie W Tan; Isba Silva; H Howard Xu
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

Review 2.  Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.

Authors:  Ming-Feng Lin; Chung-Yu Lan
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

3.  AdeRS combination codes differentiate the response to efflux pump inhibitors in tigecycline-resistant isolates of extensively drug-resistant Acinetobacter baumannii.

Authors:  J-R Sun; C-L Perng; J-C Lin; Y-S Yang; M-C Chan; T-Y Chang; F-M Lin; T-S Chiueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-18       Impact factor: 3.267

Review 4.  One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams.

Authors:  Dustin T King; Solmaz Sobhanifar; Natalie C J Strynadka
Journal:  Protein Sci       Date:  2016-03-09       Impact factor: 6.725

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.